OncoCyte Adds Lung Cancer Assay Resurrected by Razor After Previous Sale to Life Tech

OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.

By Michael Tattory| 2019-09-10T14:47:18-04:00 September 9th, 2019|News|Comments Off

About the Author: Michael Tattory

Surprise man battling rare disease helping researchers come up with treatment
Gallery
Surprise man battling rare disease helping researchers come up with treatment
Driving Drug Discovery Using Patients’ Immune Response
Gallery
Driving Drug Discovery Using Patients’ Immune Response
IPO Window, Recession, Trade War & More — 5 Biopharma Finance Experts Share Their Perspectives For 2020
Gallery
IPO Window, Recession, Trade War & More — 5 Biopharma Finance Experts Share Their Perspectives For 2020
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Gallery
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
ProQR: Developing RNA Therapies for Rare Genetic Disorders
Gallery
ProQR: Developing RNA Therapies for Rare Genetic Disorders

OncoCyte Adds Lung Cancer Assay Resurrected by Razor After Previous Sale to Life Tech

OncoCyte Adds Lung Cancer Assay Resurrected by Razor After Previous Sale to Life Tech

Share This Story, Choose Your Platform!

About the Author: Michael Tattory

Related Posts

Surprise man battling rare disease helping researchers come up with treatment

Driving Drug Discovery Using Patients’ Immune Response

IPO Window, Recession, Trade War & More — 5 Biopharma Finance Experts Share Their Perspectives For 2020

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

ProQR: Developing RNA Therapies for Rare Genetic Disorders